Response rates to single-agent carfilzomib in patients refractory or intolerant to both bortezomib and immunomodulators in trial PX-171-003-A1. This is an ASCO Meeting Abstract from the 2012 ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results